Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Multiple Sclerosis

  Free Subscription


1 Acta Neuropathol
1 BMC Neurol
1 J Neuroimmunol
4 J Neurol
1 J Neurol Neurosurg Psychiatry
1 Lancet Neurol
5 Mult Scler

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Neuropathol

  1. KESSLER W, Thomas C, Kuhlmann T
    Microglia activation in periplaque white matter in multiple sclerosis depends on age and lesion type, but does not correlate with oligodendroglial loss.
    Acta Neuropathol. 2023 Oct 28. doi: 10.1007/s00401-023-02645.
    PubMed         Abstract available

    BMC Neurol

  2. WOLF F, Nielsen J, Saliger J, Hennecken E, et al
    Multimodal agility-based exercise training (MAT) versus strength and endurance training (SET) to improve multiple sclerosis-related fatigue and fatigability during inpatient rehabilitation: a randomized controlled pilot and feasibility study [ReFEx].
    BMC Neurol. 2023;23:388.
    PubMed         Abstract available

    J Neuroimmunol

  3. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    PubMed         Abstract available

    J Neurol

  4. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.

  5. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.

  6. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    PubMed         Abstract available

  7. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

  8. PALMER AJ, Zhao T, Taylor BV, van der Mei I, et al
    Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
    J Neurol Neurosurg Psychiatry. 2023 Nov 2:jnnp-2023-332161.
    PubMed         Abstract available

    Lancet Neurol

  9. LEBRUN-FRENAY C, Kantarci O, Siva A, Azevedo CJ, et al
    Radiologically isolated syndrome.
    Lancet Neurol. 2023 Oct 4:S1474-4422(23)00281.
    PubMed         Abstract available

    Mult Scler

    The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
    Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.

  11. ONTANEDA D, Amezcua L
    Re-thinking race and geography in multiple sclerosis.
    Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.

  12. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
    Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
    PubMed         Abstract available

  13. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
    Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
    PubMed         Abstract available

  14. PORWAL MH, Obeidat AZ
    A closer look at reported colitis in association with multiple sclerosis treatments.
    Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.